Olivia Anselem
Paris Descartes University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Olivia Anselem.
Human Reproduction | 2012
C. Le Ray; S. Scherier; Olivia Anselem; A. Marszalek; Vassilis Tsatsaris; D. Cabrol; François Goffinet
BACKGROUND Although older maternal age is a risk factor for pregnancy complications, an increasing number of women delay conception until the age of 40, and some must resort to IVF with oocyte donation. Our objective was to study the association between IVF, both with and without oocyte donation, and maternal and perinatal outcomes in a population of older women. METHODS This retrospective study covered all women, aged 43 or more, who gave birth between 2008 and 2010. Univariate and multivariate analyses with logistic regression models were used to compare maternal and perinatal outcomes as a function of mode of conception: without IVF, with IVF using own oocytes or with IVF and oocyte donation. RESULTS The study included 380 women, including 40 who had IVF without oocyte donation (10.5%) and 104 who had both (27.4%). There were 326 singleton and 54 multiple pregnancies. Overall, the complication rate was high: 8.7% pre-eclampsia, 6.1% gestational diabetes, 20.2% preterm delivery and 8.2% very preterm delivery (before 33 weeks), 44.8% Cesarean sections and 7.4% severe post-partum hemorrhage (PPH). The pre-eclampsia rate differed significantly between the groups (3.8% after no IVF, 10.0% after IVF only and 19.2% after IVF with oocyte donation, P< 0.001). After adjustment, the risk of pre-eclampsia was significantly higher in women with donated oocytes compared with pregnant women without IVF [adjusted OR = 3.3 (1.2-8.9)]. The rate of twin pregnancy was significantly higher in women with IVF and oocyte donation (39.4 versus 15.0% with IVF only and 2.5% without IVF, P< 0.001). Twin pregnancy was significantly associated with the risk of preterm delivery [adjusted OR = 8.9 (4.0-19.9)] and PPH [adjusted OR = 3.5 (1.3-9.5)]. CONCLUSION In women aged 43 years or older, pregnancies obtained by IVF with oocyte donation are associated with higher rates of pre-eclampsia and twin pregnancies than those obtained without IVF or with IVF using their own oocytes.
PLOS ONE | 2012
Jeanne Sibiude; Jean Guibourdenche; Marie-Danielle Dionne; Camille Le Ray; Olivia Anselem; Raphaël Serreau; François Goffinet; Vassilis Tsatsaris
Background The circulating concentration of PlGF is reported to be lower in patients experiencing preeclampsia and patients delivering a small for gestational age (SGA) neonate. To evaluate the predictive value of circulating PlGF for preeclampsia and adverse outcome in patients with suspected preeclampsia or intrauterine growth restriction (IUGR). Methodology/Principal Findings A double blind prospective study. We enrolled 96 women for suspected preeclampsia or IUGR, and measured plasma levels of PlGF (Triage®) at enrolment. We defined adverse outcome as severe preeclampsia, SGA neonate (<10th centile) or elective delivery for maternal or fetal complication. Severe adverse outcome was studied among patients included <34 weeks gestation (WG) and defined as eclampsia, HELLP syndrome, very SGA (<3rd centile) or elective delivery <34 WG. The mean logtransformed PlGF level was lower for women who experienced preeclampsia (2.9 vs 3.7, p = 0.02), and was markedly lower for patients who experienced adverse outcome (2.9 vs 4.3, p<0.001). The odds of presenting an adverse outcome were higher for the lowest tertile of PlGF compared to the higher (OR = 13 , 95% CI [3–50]). For severe adverse outcome, odds were respectively for the lowest and intermediate tertile as compared with the higher tertile : OR = 216, 95% CI [18–2571]; and OR = 17, 95% CI [3–94]. When included <34 WG, patients with a PlGF level <12 pg/ml experienced a severe adverse outcome in 96% of cases (24/25), and only 1 of 20 patients with a PlGF level >5th centile experienced a severe adverse outcome within 15 days (5%). Conclusions/Significance Among women with suspected preeclampsia or IUGR, PlGF helps identify women who will experience an adverse outcome and those who will not within a time period of 15 days.
Prenatal Diagnosis | 2016
Lucie Orhant; Olivia Anselem; Mélanie Fradin; Pierre Hadrien Becker; Caroline Beugnet; Nathalie Deburgrave; Gilles Tafuri; Franck Letourneur; François Goffinet; Laïla Allach El Khattabi; Thierry Bienvenu; Vassilis Tsatsaris; Juliette Nectoux
Achondroplasia is generally detected by abnormal prenatal ultrasound findings in the third trimester of pregnancy and then confirmed by molecular genetic testing of fetal genomic DNA obtained by aspiration of amniotic fluid. This invasive procedure presents a small but significant risk for both the fetus and mother. Therefore, non‐invasive procedures using cell‐free fetal DNA in maternal plasma have been developed for the detection of the fetal achondroplasia mutations.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2013
Juliana Patkai; Thomas Schmitz; Olivia Anselem; Siham Mokbat; Pierre-Henri Jarreau; François Goffinet; Elie Azria
OBJECTIVE To assess the impact of extreme preterm premature rupture of membranes (PPROM) <25 weeks of gestation on preterm child outcome. STUDY DESIGN Retrospective study comparing the neonatal and 2-year outcomes of infants exposed to extremely PPROM <25 weeks with a non-exposed group of neonates in a tertiary care referral centre located in Paris, France, between 2003 and 2007. All women with singleton pregnancy and PPROM between 15(0/7) and 24(6/7) weeks of gestation were recruited. For each infant born alive, the next inborn neonate matched for gestational age and sex was selected as a control among neonates born alive after spontaneous preterm labour with intact membranes. The main outcome measures were neonatal outcome assessed by a combined criterion of adverse neonatal outcomes and the two-year neurodevelopmental outcome assessed by developmental Brunet-Lézine tests and neurological examinations. RESULTS In 78 cases of extremely PPROM, 22 live births occurred at a mean gestational age of 26(5/7) weeks. The percentage of neonates with adverse neonatal outcomes was significantly higher among PPROM than non-exposed cases (68.2 versus 27.3%). At 2 years of age, children from the PPROM group were more likely to have delayed acquisitions (64.3 versus 15.8%) and behavioural disorders (57.1 versus 15.8%). Mean Brunet-Lézine language score was significantly lower among those infants (78.9 versus 96.8). CONCLUSION PPROM <25 weeks is associated with increased neonatal mortality and morbidity and with increased risks of delayed acquisitions, behavioural disorders and lower language performance scores at 2 years in comparison with matched preterm neonates born after spontaneous preterm labour with intact membranes.
International Journal of Gynecology & Obstetrics | 2011
Olivia Anselem; Guillaume Girard; Alain Stepanian; Elie Azria; Laurent Mandelbrot
To determine whether ethnic origin is related to the clinical and biologic expression of pre‐eclampsia.
Journal De Gynecologie Obstetrique Et Biologie De La Reproduction | 2011
C. Le Ray; Olivia Anselem
Journal de Gynecologie Obstetrique et Biologie de la Reproduction - Vol. 40 - N° 8 - p. 703-708The duration of pregnancy is between 280 and 290 days from the first day of the last menstrual period and varies according to the literature, the authors, the calculation methods and the characteristics of women. Assuming that the date of beginning of pregnancy is known, the expected date of delivery varies depending on the length of gestation. Thus, in literature and in obstetric practice, there is no consensus on the definition of expected date of delivery. From a medical point of view, it seems important to fix the date from which the monitoring should start and from which an induction of labour should be considered. Thus, arbitrarily, we can consider that the term period corresponds to a time interval located between 37(+0) SA and 41(+6) SA and the post-term period begins from 42(+0) SA. Because maternal and fetal risks increase at the end of the pregnancy, one can speak, arbitrarily, of prolonged pregnancy from 41(+0) SA (expert opinion).
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2018
Marie-Victoire Senat; Olivia Anselem; Olivier Picone; Laurent Renesme; Nicolas Sananes; Christelle Vauloup-Fellous; Yann Sellier; Jean-Pierre Laplace; Loïc Sentilhes
OBJECTIVE Identify measures to diagnose, prevent, and treat genital herpes infection during pregnancy and childbirth as well as neonatal herpes infection. MATERIALS AND METHODS Bibliographic search from the Medline and Cochrane Library databases and review of international clinical practice guidelines. RESULTS Genital herpes lesions are most often due to HSV-2 (LE2). The risk of HSV seroconversion during pregnancy is 1-5% (LE2). Genital herpes lesions during pregnancy in a woman with a history of genital herpes is a recurrence. In this situation, there is no need for virologic confirmation (Grade B). In pregnant women with genital lesions who report they have not previously had genital herpes, virological confirmation by PCR and identifying the specific IgG type is necessary (professional consensus). A first episode of genital herpes during pregnancy should be treated with aciclovir (200 mg 5 times daily) or valaciclovir (1000 mg twice daily) for 5-10 days (Grade C), and recurrent herpes during pregnancy with aciclovir (200 mg 5 times daily) or valaciclovir (500 mg twice daily) (Grade C). The risk of neonatal herpes is estimated at between 25% and 44% if a non primary and primary first genital herpes episode is ongoing at delivery (LE2) and 1% for a recurrence (LE3). Antiviral prophylaxis should be offered to women with either a first or recurrent episode of genital herpes during pregnancy from 36 weeks of gestation until delivery (Grade B). Routine prophylaxis is not recommended for women with a history of genital herpes but no recurrence during pregnancy (professional consensus). A cesarean delivery is recommended if a first episode of genital herpes is suspected (or confirmed) at the onset of labor (Grade B) or if it occured less than 6 weeks before delivery (professional consensus) or in the event of premature rupture of the membranes at term. When a recurrence of genital herpes is underway at the onset of labor, cesarean delivery is most likely to be considered when the membranes are intact and vaginal delivery in cases of prolonged rupture of membranes (professional consensus). Neonatal herpes is rare and mainly due to HSV-1 (LE3). In most cases of neonatal herpes, mothers have no history of genital herpes (LE3). When neonatal herpes is suspected, various samples (blood and cerebrospinal fluid) for HSV PCR must be taken to confirm the diagnosis (professional consensus). Any newborn with suspected neonatal herpes should be treated with intravenous acyclovir (20 mg/kg 3 times daily) (grade A) before the PCR results are available (professional consensus). The duration of the treatment depends on the clinical form (professional consensus) CONCLUSION: There is no formal evidence that it is possible to reduce the risk of neonatal herpes in genital herpes during pregnancy. However, appropriate care can reduce the symptoms associated with herpes and the risk of recurrence at term, as well as cesarean rate because of herpes lesions.
Expert Review of Vaccines | 2018
Paul Loubet; Olivia Anselem; Odile Launay
ABSTRACT Introduction: Vaccination in pregnancy has been shown to be effective for the prevention of influenza and pertussis in infants, providing support for similar strategies to prevent group B streptococcus and respiratory syncytial virus infections that represent a large burden in pediatric population. Areas covered: This review addresses the principle of maternal immunization, efficacy and safety of both pertussis and seasonal influenza vaccines and presents available data on group B streptococcus and respiratory syncytial virus that are in development for administration during pregnancy. Expert commentary: Complementary data is needed to help in understanding pertussis vaccine mechanisms, improving influenza vaccine efficacy and addressing the interference phenomenon which is when maternal antibodies interfere with the infant vaccine response. Several knowledge gaps need to be filled in group B streptococcus and respiratory syncytial virus vaccines research.
Gynécologie Obstétrique Fertilité & Sénologie | 2017
Marie-Victoire Senat; Olivia Anselem; Olivier Picone; L. Renesme; N. Sananès; Christelle Vauloup-Fellous; Y. Sellier; J.-P. Laplace; L. Sentilhes
OBJECTIVE Identify measures to diagnose, prevent and treat genital herpes infection during pregnancy and childbirth and neonatal infection. METHODS Bibliographic search from Medline, Cochrane Library databases and research of international clinical practice guidelines. RESULTS Genital herpes lesion is most often due to HSV2 (LE2). The risk of HSV seroconversion during pregnancy is 1 to 5% (LE2). Genital herpes ulceration during pregnancy in a woman with history of genital herpes corresponds with a recurrence. In this situation, there is no need for virologic confirmation (grade B). In case of genital lesions in a pregnant woman that do not report any genital herpes before, it is recommended to perform a virological confirmation by PCR and HSV type specific IgG (Professional consensus). In case of first episode genital herpes during pregnancy, antiviral treatment with acyclovir (200mg 5 times daily) or valacyclovir (1000mg twice daily) for 5 to 10 days is recommended (grade C). In case of recurrent herpes during pregnancy, antiviral therapy with acyclovir (200mg 5 times daily) or valacyclovir (500mg twice daily) can be administered (grade C). The risk of neonatal herpes is estimated between 25% and 44% in case of initial episode (LE2) and 1% in case of recurrence (LE3) at the time of delivery. Antiviral prophylaxis should be offered for women with first episode genital herpes or recurrent genital herpes during pregnancy from 36 weeks of gestation and until delivery (grade B). In case of a history of genital herpes without episode of recurrence during pregnancy, it is not recommended routinely offer a prophylactic treatment (professional consensus). A cesarean section should be performed if there is a suspicion of first episode genital herpes at the onset of labor (grade B), in the event of premature rupture of the membranes at term (professional consensus), or in case of first episode genital herpes less than 6 weeks before delivery (professional consensus). In case of recurrent genital herpes at the onset of labor, cesarean delivery will be all the more considered if the membranes are intact and vaginal delivery will be all the more considered in case of prolonged rupture of membranes (professional consensus). Neonatal herpes is rare and mainly due to HSV-1 (LE3). In most of the case of neonatal herpes, the mothers have no history of genital herpes (LE 3). In case of suspicion of neonatal herpes, different samples (blood and cerebrospinal fluid) for HSV PCR must be carried out to confirm the diagnosis (professional consensus). Any newborn suspected of neonatal herpes should be treated with intravenous acyclovir (60mg/kgs/day 3 times daily) (grade A) prior to the results of HSV PCR (professional consensus). The duration of the treatment depends on the clinical form (professional consensus) CONCLUSION: There is no formal evidence that it is possible to reduce the risk of neonatal herpes in genital herpes during pregnancy. However, appropriate care can reduce the symptoms associated with herpes, the risk of recurrence term and the cesarean rate performed to decrease the risk of neonatal herpes.
Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie | 2016
Olivia Anselem; Odile Launay
Les femmes ayant un projet de grossesse doivent recevoir une information sur les risques infectieux en periode perinatale et les vaccinations recommandees. En France, les principales vaccinations qui doivent etre mises a jour, si besoin, en prevision d’une grossesse, sont la coqueluche, la rougeole, la rubeole et la varicelle. L’interrogatoire permet de rechercher un antecedent de varicelle clinique et le controle du carnet de vaccination permet de verifier le statut vaccinal vis-a-vis de la coqueluche, de la rougeole, de la rubeole et le cas echeant de la varicelle. En cas d’impossibilite de recueillir des informations relatives aux vaccinations varicelle, rougeole et rubeole, des serologies peuvent etre proposees. Si le dernier rappel vaccinal contre la coqueluche date de plus de dix ans, un rappel avec un vaccin diphterie-tetanos-polio-coqueluche acellulaire (dTPca) est recommande avant la grossesse. La vaccination coqueluche sera proposee au cours de la grossesse au conjoint et a l’entourage du futur nouveau-ne afin de diminuer le risque de coqueluche neonatale (strategie du cocooning). Les vaccins contre la varicelle, la rougeole ou la rubeole sont recommandes chez les femmes non a jour. Ces vaccins vivants ne doivent pas etre administres pendant la grossesse. Les vaccins varicelle et rougeole-oreillons-rubeole (ROR) ne peuvent pas etre administres le meme jour. Il faut respecter un delai de un mois entre l’injection de deux vaccins vivants.